Cibus, Inc.

Cibus, Inc. develops gene-edited plant traits using its proprietary RTDS platform, with a current focus on weed-management traits for rice and canola. The company also pursues partner-funded sustainable ingredients and other trait programs, monetizing its technology through collaboration agreements, licenses, and future royalties rather than selling finished farm products.

−2 517,3 %

−3 492,3 %

−14,6 %

0.72

0.72

— Cibus, Inc.
%
Gene editing platform0% Core RTDS technology used to edit elite germplasm with targeted trait changes.
Rice traits45% Herbicide tolerance and stacked trait lines for rice commercialization.
Canola and WOSR traits15% Trait development for canola and winter oilseed rape, including disease resistance work.
Soybean traits10% Soybean editing programs such as HT2 used to expand the platform and future partnerships.
Sustainable ingredients and biofragrance30% Partner-supported ingredient and fermentation-based product development programs.

Cibus sells primarily to seed companies, agricultural partners, and prospective commercial licensees that want...

  • Seed companies and breeding partnersprimary

    Buy trait access and edited germplasm to incorporate Cibus traits into commercial seed lines.

  • Agricultural collaboration partnersprimary

    Fund contract research and development milestones for rice, canola, and other traits.

  • Consumer-packaged goods partnersecondary

    Supports sustainable ingredients development and helps fund commercialization work.

  • Prospective rice commercial customersprimary

    Engage for rice herbicide tolerance traits in geographies where rice is cultivated globally.

  • Future licensees and royalty partnersemerging

    Would commercialize products containing Cibus intellectual property and pay fees or royalties.

Cibus is headquartered in the United States and conducts development work across the U.S...

  • •United States is the home market and a key regulatory reference point
  • •Ecuador provided regulatory validation for RTDS technologies
  • •Latin America is a near-term rice commercialization focus
  • •UK regulatory progress may lower barriers for precision-bred organisms
  • •Global rice-growing geographies are the target market for future launches

Cibus is narrowing its focus to weed management in rice and partner-supported sustainable ingredients to preserve...

01
Commercialize rice herbicide tolerance traitsshort-term

Rice is the clearest near-term path to revenue and customer adoption.

02
Convert RTDS validation into broader regulatory acceptancemedium-term

Lower regulatory barriers should shorten development cycles and expand addressable markets.

03
Preserve capital and reduce burnshort-term

The company remains loss-making and needs runway to reach commercialization milestones.

04
Monetize partner-funded sustainable ingredientsmedium-term

This provides non-dilutive funding and diversifies the revenue base.

Cibus remains an early-commercial biotech company with limited revenue, ongoing losses, and dependence on external...

high

Financing and liquidity risk

The company has incurred losses since inception and expects continued losses before commercialization scales.

Scope
Cash on hand, future equity/debt access, and commercialization timing
Materiality
high
high

Commercialization delay in rice traits

Revenue depends on moving edited traits into customer germplasm and achieving regulatory clearance and adoption.

Scope
Latin America launch timing, U.S. expansion, customer conversion
Materiality
high
high

Regulatory risk

Gene-edited crop commercialization depends on evolving rules in each market.

Scope
United States, Ecuador, UK, EU
Materiality
high
medium

Restructuring execution risk

Workforce and facility reductions may reduce institutional knowledge and disrupt development.

Scope
Talent retention, morale, operational continuity
Materiality
medium
medium

Litigation and contingent liability risk

The company accrued a liability related to a Ninth Circuit decision and insurance proceeds repayment.

Scope
Cash outflow and earnings impact
Materiality
medium
Revenue recognition for collaboration agreements
Quarterly revenue volatility
Goodwill impairment
Non-cash operating loss volatility
Litigation liability accrual
Balance sheet liability and earnings impact
Going concern and liquidity estimates
Disclosure risk and investor perception of runway
Restructuring and lease exit accounting
Expense timing and cash usage

Cibus Nordic Real Estate

CIBUS.ST · Real Estate

PYXUS INTERNATIONAL, INC.

PYYX · Wholesale-Farm Product Raw Materials

Terns Pharmaceuticals, Inc.

Pharmaceutical Preparations

Beam Therapeutics Inc.

BEAM · Biological Products, (No Diagnostic Substances)

Ginkgo Bioworks Holdings, Inc.

DNA · Biological Products, (No Diagnostic Substances)

Caribou Biosciences, Inc.

CRBU · Biological Products, (No Diagnostic Substances)

: 28/04/2026